Literature DB >> 25062744

Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.

Parag H Joshi1, Peter P Toth2, Seth T Lirette3, Michael E Griswold3, Joseph M Massaro4, Seth S Martin5, Michael J Blaha5, Krishnaji R Kulkarni6, Arif A Khokhar7, Adolfo Correa8, Ralph B D'Agustino9, Steven R Jones5.   

Abstract

AIMS: We aimed to clarify the associations of high-density lipoprotein cholesterol (HDL-C) subclasses with incident coronary heart disease (CHD) in two large primary prevention cohorts.
METHODS: We measured cholesterol at baseline from the two major HDL subfractions (larger, more buoyant HDL2 and smaller, denser HDL3) separated by density gradient ultracentrifugation in 4114 (mean age 53.8 years; 64% female) African American participants from the Jackson Heart Study and 818 (mean age 57.3 years, 52% female) predominantly Caucasian participants from the Framingham Offspring Cohort Study. Multivariable adjusted hazard ratios (HRs) for HDL-C and its subclasses were derived from Cox proportional hazards regression models to estimate associations with incident CHD events including myocardial infarction, CHD death, and revascularization. Analyses were performed for each cohort separately and as a combined population.
RESULTS: In models adjusted for cardiovascular risk factors for the combined population, HDL3-C (HR 0.76 per SD increase; 95% confidence interval (CI), 0.62-0.94; p = 0.01), rather than HDL2-C (HR 0.88 per SD; 95% CI, 0.72-1.09; p = 0.24) drove the inverse association of HDL-C (HR 0.79 per SD; 95% CI, 0.64-0.98; p = 0.03) with CHD. Similar associations were seen in multivariable analyses within each cohort including after adjusting for apolipoprotein A1 in the Jackson Heart Study.
CONCLUSION: Smaller, denser HDL3-C levels are primarily responsible for the inverse association between HDL-C and incident CHD in this diverse group of primary prevention subjects. These findings have important implications ranging from considerations of HDL biology to interpretations of clinical trials utilizing HDL-C therapeutics. © The European Society of Cardiology 2014.

Entities:  

Keywords:  High-density lipoprotein cholesterol; coronary heart disease; primary prevention

Mesh:

Substances:

Year:  2014        PMID: 25062744      PMCID: PMC4312248          DOI: 10.1177/2047487314543890

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  41 in total

Review 1.  The protein cargo of HDL: implications for vascular wall biology and therapeutics.

Authors:  Jay W Heinecke
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

2.  Jekyll and Hyde of HDL: a lipoprotein with a split personality.

Authors:  Prediman K Shah
Journal:  Eur Heart J       Date:  2013-09-23       Impact factor: 29.983

3.  HDL and cardiovascular-disease risk--time for a new approach?

Authors:  Jay Heinecke
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 4.  High-density lipoprotein subclasses and their relationship to cardiovascular disease.

Authors:  H Robert Superko; Lakshmana Pendyala; Paul T Williams; Katherine M Momary; Spencer B King; Brenda C Garrett
Journal:  J Clin Lipidol       Date:  2012-03-23       Impact factor: 4.766

Review 5.  HDL and cholesterol: life after the divorce?

Authors:  Kasey C Vickers; Alan T Remaley
Journal:  J Lipid Res       Date:  2013-03-19       Impact factor: 5.922

6.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

7.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

8.  High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease.

Authors:  Akintunde O Akinkuolie; Nina P Paynter; Latha Padmanabhan; Samia Mora
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-11-18

Review 9.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Authors:  M John Chapman; Henry N Ginsberg; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen; Gerald F Watts
Journal:  Eur Heart J       Date:  2011-04-29       Impact factor: 29.983

10.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Authors: 
Journal:  Eur Heart J       Date:  2013-02-26       Impact factor: 29.983

View more
  29 in total

1.  Refocusing the AIM on HDL in the metabolic syndrome.

Authors:  Robert W McGarrah
Journal:  Atherosclerosis       Date:  2016-07-02       Impact factor: 5.162

2.  Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.

Authors:  John J Albers; April Slee; Jerome L Fleg; Kevin D O'Brien; Santica M Marcovina
Journal:  Atherosclerosis       Date:  2016-06-11       Impact factor: 5.162

3.  Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies.

Authors:  Frank M Sacks; Liang Liang; Jeremy D Furtado; Tianxi Cai; W Sean Davidson; Zeling He; Robyn L McClelland; Eric B Rimm; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 8.311

4.  A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.

Authors:  Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327

Review 5.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

6.  Polyphenol rich olive oils improve lipoprotein particle atherogenic ratios and subclasses profile: A randomized, crossover, controlled trial.

Authors:  Sara Fernández-Castillejo; Rosa-Maria Valls; Olga Castañer; Laura Rubió; Úrsula Catalán; Anna Pedret; Alba Macià; Maureen L Sampson; María-Isabel Covas; Montserrat Fitó; Maria-José Motilva; Alan T Remaley; Rosa Solà
Journal:  Mol Nutr Food Res       Date:  2016-05-06       Impact factor: 5.914

7.  Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol.

Authors:  Marios K Georgakis; Rainer Malik; Christopher D Anderson; Klaus G Parhofer; Jemma C Hopewell; Martin Dichgans
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

8.  Effects of a diet naturally rich in polyphenols on lipid composition of postprandial lipoproteins in high cardiometabolic risk individuals: an ancillary analysis of a randomized controlled trial.

Authors:  Giuseppe Della Pepa; Claudia Vetrani; Marilena Vitale; Lutgarda Bozzetto; Giuseppina Costabile; Paola Cipriano; Anna Mangione; Lidia Patti; Gabriele Riccardi; Angela Albarosa Rivellese; Giovanni Annuzzi
Journal:  Eur J Clin Nutr       Date:  2019-06-27       Impact factor: 4.016

9.  Large HDL2 combined with inflammatory factors as superior predictors for coronary artery disease than small HDL3.

Authors:  Xiaoying Wu; Zhijian He; Runlu Sun; Xiangkun Xie; Qingqun Chen; Junjie Wang; Jinlan Bao; Jingjing Huang; Yuan Jiang; Yuling Zhang; Jingfeng Wang
Journal:  Ann Transl Med       Date:  2021-04

10.  Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study.

Authors:  Florencia S Pierini; Eliana Botta; Enrique R Soriano; Maximiliano Martin; Laura Boero; Tomás Meroño; María Soledad Saez; Ezequiel Lozano Chiappe; Osvaldo Cerda; Gustavo Citera; Ignacio Gandino; Javier Rosa; Patricia Sorroche; Anatol Kontush; Fernando Brites
Journal:  Rheumatol Ther       Date:  2021-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.